{"entity":{"id":"nct00551525","kind":"trial","name":"Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer","aka":[],"tldr":"A phase 2 trial of Samarium-153 lexidronam in Prostate cancer, run by Radiation Therapy Oncology Group, completed.","summary":"Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer is a phase 2 interventional study registered as NCT00551525 by Radiation Therapy Oncology Group, with 67 participants recorded, started 2008-04 and reaching its primary completion in 2014-07. Interventions recorded: Radiotherapy, Samarium 153. Conditions recorded: Prostate Cancer.\n\nLinked to the drug Samarium-153 lexidronam because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT00551525","url":"https://clinicaltrials.gov/study/NCT00551525"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate","prostate-high-risk"],"sections":[],"technologies":[],"targets":[],"drugs":["samarium-153-lexidronam"],"companies":["nrg-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00551525","phase":"2","setting":"A Phase II Trial of Samarium 153 Followed by Salvage Prostatic Fossa 3D-CRT or IMRT Irradiation in High-Risk, Clinically Non-Metastatic Prostate Cancer After Radical Prostatectomy","sponsor":"Radiation Therapy Oncology Group","started":"2008-04","yearReported":2017,"enrolled":67,"enrolledBasis":"registry","outcomes":[{"endpoint":"Proportion of Patients With PSA Response (pt) Within 12 Weeks of Samarium 153 Administration","primary":true,"unit":"%","arms":[{"name":"Radiotherapy + Samarium 153","n":52,"value":7,"note":"Figures from the ClinicalTrials.gov results section (first posted 2017-07-25), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT00551525?tab=results"}]},"route":"/trials/nct00551525/","neighbours":{"cancer":[{"id":"prostate-high-risk","kind":"cancer","name":"Localised prostate cancer, high and very high risk","route":"/cancers/prostate-high-risk/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"samarium-153-lexidronam","kind":"drug","name":"Samarium-153 lexidronam","route":"/drugs/samarium-153-lexidronam/"}],"company":[{"id":"nrg-oncology","kind":"company","name":"NRG Oncology","route":"/companies/nrg-oncology/"}]}}